Citi analyst Samantha Semenkow opened an “upside 30-day catalyst watch” on shares of Wave Life Sciences (WVE) while keeping a Buy rating on the shares with a $30 price target Citi sees share upside on the company’s WVE-007 data in obesity patients. It believes a positive readout could increase strategic interest in WVE-007.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on WVE:
- Wave Life Sciences: Differentiated Obesity Franchise and RNA-Editing Pipeline Momentum Justify Buy Rating
- Wave Life Sciences Highlights 2025 Results and Obesity Progress
- Wave Life Sciences reports Q4 EPS (30c), consensus (26c)
- Wave Life Sciences: Asymmetric Upside from Obesity and AATD RNA Editing Catalysts Supports Buy Rating
- WVE Earnings Report this Week: Is It a Buy, Ahead of Earnings?